Novo Nordisk is shifting strategy under new CEO Maziar Mike Doustdar, instituting a global hiring freeze for non‑key roles and warning of possible further job cuts as it seeks to restore competitiveness after losing U.S. leadership in obesity drugs to Eli Lilly. The company, which employs over 78,000 people, has said the pause is part of broader cost‑cutting and efficiency measures; most current openings are in the U.S. and China, with only eight listed in Denmark. #NovoNordisk #NVO

Shares rose on Monday after the U.S. FDA approved Wegovy for treatment of metabolically associated steatohepatitis, a severe form of fatty‑liver disease that can lead to cirrhosis or cancer. Analysts note the market for this indication is smaller than obesity or diabetes but could help stabilize the company amid intensifying competition from Eli Lilly and others. "This is quite a promising sign," analyst Branislav Soták said, adding it is "not a fundamental turnaround yet, but a signal the company could protect part of its market." He also said he had viewed an entry price around $60 per share as attractive and that the stock was trading near $52, calling it still a speculative investment. #Wegovy #NASH #LLY

Novo Nordisk also signaled efforts to strengthen international ties: chairman Helge Lund met Chinese Vice President Han Zheng, who urged deeper cooperation between global pharmaceutical firms and China as the country continues market opening and reforms. #FiatNews